NASDAQ:ALNY
Alnylam Pharmaceuticals Stock News
$147.76
-1.62 (-1.08%)
At Close: May 24, 2024
Goldman Sachs Variable Insurance Trust Growth Opportunities Fund Buys Novavax Inc, Ryan ...
04:38am, Saturday, 18'th Dec 2021 GuruFocus
Related Stocks: PXD , FTV , UTZ , EXPE , TWTR , CMI , NVAX , RYAN , ALNY , FOUR , EPAM , DISCA , WYNN , AVLR , AGIO , SPG , PINS , WING ,
Goldman Sachs Variable Insurance Trust Strategic Growth Fund Buys Moderna Inc, Alnylam ...
03:38am, Saturday, 18'th Dec 2021 GuruFocus
Related Stocks: VRSK , MKC , UNP , BA , MRNA , ALNY , AFRM , SHOP , DLO , TOST , GPN , BMY , AI ,
Analysts Expect Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Will Announce Quarterly Sales of $232.16 Million
09:46pm, Friday, 17'th Dec 2021 Dakota Financial News
Wall Street brokerages expect Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to post sales of $232.16 million for the current quarter, Zacks Investment Research reports. Seven analysts have made estimates for Alnylam Pharmaceuticals earnings, with estimates ranging from $214.75 million to $244.40 million. Alnylam Pharmaceuticals posted sales of $163.56 million in the same quarter last year, which would []
M&A madness: Top analyst on how biotech could rebound in 2022
06:43pm, Wednesday, 15'th Dec 2021
Michael Yee, Jefferies, on whether there's more M&A to come in the biotech space. With CNBC's Melissa Lee and the Fast Money traders, Tim Seymour, Steve Grasso, Pete Najarian and Karen Finerman.
Alnylam (ALNY) Files for Oxlumo Label Expansion in US & EU
06:10pm, Wednesday, 15'th Dec 2021 FXNews24
Alnylam Pharmaceuticals, Inc. ALNY announced that it has submitted a supplemental new drug application (sNDA) to the FDA and a Type II filing variation to the European Medicines Agency (EMA) for its RNAi therapeutic, lumasiran for the reduction of plasma oxalate in the treatment of patients with advanced primary hyperoxaluria type 1 (PH1). The latest [] The post Alnylam (ALNY) Files for Oxlumo Label Expansion in US & EU appeared first on UK Stocks, Forex, Commodities, Crypto, Live Market News- Daily Forex News .
Alnylam (ALNY) Files for Oxlumo Label Expansion in US & EU
12:20pm, Wednesday, 15'th Dec 2021
Alnylam (ALNY) files regulatory applications to the FDA and the EMA, seeking approval for a new indication of Oxlumo for the treatment of advanced primary hyperoxaluria type 1.
2 Mid-Cap Biopharma Stocks BofA Securities Recommends For 2022
04:48pm, Tuesday, 14'th Dec 2021
Biotech stocks are risky investments and to make a profit informed decision-making is needed. BofA Securities announced its top mid-cap biopharma picks in a note released Tuesday.
Alnylam Submits Applications In U.S, EU To Support Label Expansion For Oxlumo For PH1 Treatment
12:47pm, Tuesday, 14'th Dec 2021 Business Insider Markets
(RTTNews) - Alnylam Pharmaceuticals Inc. (ALNY) said that it has submitted a supplemental New Drug Application or sNDA to the U.S. Food and Drug Administration and Type II Filing Variation to the European Medicines Agency for lumasiran, an investigational RNAi therapeutic targeting hydroxyacid oxidase 1 (HAO1) - the gene encoding glycolate…
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) and Type II Filing Variation to the European Medicines Agency (EMA) for lumasiran, an investigational RNAi therapeutic targeting hydroxyacid oxidase 1 (HAO1) the gene encoding glycolate oxidase (GO) for the reduction of plasma oxalate in the treatment
Antisense & RNAi Therapeutics Market 2021 report helps the clients to take business decisions and to understand strategies of major players in the industry. The report also calls for market- driven results deriving feasibility studies for client needs. Market Insights
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Expected to Announce Quarterly Sales of $232.16 Million
07:28am, Sunday, 12'th Dec 2021 ETF Daily News
Equities research analysts expect Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to post sales of $232.16 million for the current fiscal quarter, Zacks reports. Seven analysts have provided estimates for Alnylam Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $214.75 million and the highest estimate coming in at $244.40 million. Alnylam Pharmaceuticals posted sales of $163.56 […] The post Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Expected to Announce Quarterly Sales of $232.16 Million appeared first on ETF Daily News .
Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY) Gain Of 28.9% Compared To 52-Week Low; YTD Rise 33.61% What Should You Do Now?
01:30pm, Saturday, 11'th Dec 2021 Marketing Sentinel
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY)s traded shares stood at 0.39 million during the last session, with the companys beta value hitting 0.91. At the close of trading, the stocks price was $173.65, to imply an increase of 0.68% or $1.18 in intraday trading. The ALNY shares 52-week high remains $212.00, putting it -22.08% down since that Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY) Gain Of 28.9% Compared To 52-Week Low; YTD Rise 33.61% What Should You Do Now? Read More »
3 Under-the-Radar Biotech Stocks to Buy in 2022
06:00am, Saturday, 11'th Dec 2021
They may deliver major gains down the road.
RNA Based Therapeutics Market Hit Stunning Double Digit CAGR +28% With Renowned Key Players ISIS pharmaceuticals, Quark Pharmaceuticals, Alnylam Pharmaceuticals
01:38pm, Thursday, 09'th Dec 2021 OpenPR
RNA based mostly medicine Market has garnered vital attention within the recent years because of its potential to treat type of chronic diseases like cancer, diabetes, AIDS, infectious disease and sure vas conditions. RNA Based Therapeutics Market is expected to garner
Tekla Healthcare Investors Buys Amgen Inc, Guardant Health Inc, Icon PLC, Sells Abbott ...
12:38am, Thursday, 09'th Dec 2021 GuruFocus
Related Stocks: AMGN , GH , IDXX , ALNY , NVAX , SRPT , ICLR , BHVN , CTLT , CRBU , AZN , RLYB , ABT , ASND , NBIX , DXCM , ARNA , ARGX , DCPH , BBIO , RMD , BPMC , ALLK , IOVA ,